In this video, Isaac Y. Kim, MD, PhD, MBA, discusses why immunotherapy may ultimately represent the next major advance in prostate cancer treatment.
Isaac Y. Kim, MD, PhD, MBA
Advertisement
Articles by Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, reflects on concerning trends in prostate cancer mortality, emphasizing how advances in diagnostics, treatment, and artificial intelligence may improve outcomes in the future.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
European Commission approves perioperative EV/pembrolizumab for cisplatin-ineligible MIBC
2
NCCN recommends ctDNA-MRD testing to guide adjuvant treatment post-cystectomy
3
Lymph Node Dissection Following Systemic Therapy in MIBC
4
Fred Saad, MD, highlights PSA end points from the phase 3 PSMAddition trial
5